Kuros Biosciences AG

OTCPK:CSBT.F Stock Report

Market Cap: US$982.8m

Kuros Biosciences Management

Management criteria checks 2/4

Kuros Biosciences' CEO is Chris Fair, appointed in Oct 2023, has a tenure of 1.08 years. total yearly compensation is CHF1.34M, comprised of 24.6% salary and 75.4% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth $3.49M. The average tenure of the management team and the board of directors is 1.1 years and 6.2 years respectively.

Key information

Chris Fair

Chief executive officer

CHF 1.3m

Total compensation

CEO salary percentage24.6%
CEO tenure1.1yrs
CEO ownership0.4%
Management average tenure1.1yrs
Board average tenure6.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Fair's remuneration changed compared to Kuros Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CHF 9m

Mar 31 2024n/an/a

-CHF 11m

Dec 31 2023CHF 1mCHF 329k

-CHF 14m

Sep 30 2023n/an/a

-CHF 15m

Jun 30 2023n/an/a

-CHF 16m

Mar 31 2023n/an/a

-CHF 15m

Dec 31 2022CHF 36kn/a

-CHF 15m

Sep 30 2022n/an/a

-CHF 13m

Jun 30 2022n/an/a

-CHF 11m

Mar 31 2022n/an/a

-CHF 9m

Dec 31 2021CHF 36kn/a

-CHF 8m

Compensation vs Market: Chris's total compensation ($USD1.51M) is below average for companies of similar size in the US market ($USD3.18M).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

CEO

Chris Fair (54 yo)

1.1yrs

Tenure

CHF 1,337,700

Compensation

Mr. Christopher T. Fair, also known as Chris, serves as the Chief Executive Officer At Kuros Biosciences AG since October 2023 and serves as Director since April 17, 2024. He was the Chief Operating Office...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Fair
CEO & Director1.1yrsCHF 1.34m0.35%
$ 3.5m
Daniel Geiger
Chief Financial Officer1.5yrsno datano data
Sjoerd Musters
COO & GM of BV1.1yrsno datano data
Joost de Bruijn
President of Innovation and Strategy & Executive Director1.1yrsCHF 873.70kno data
G. Ross
Senior Vice President of Marketing & Business Developmentless than a yearno datano data
Nikki Coleman
Vice President of Global Human Resourcesless than a yearno datano data
Philippe Saudan
Chief Development Officer8.3yrsno datano data
John Griffin
Chief Commercial Officer6.6yrsno datano data
Katherine Sage
Senior Vice President of Medical & Clinical Affairsless than a yearno datano data
Virginia Jamieson
Consultant6.5yrsno datano data

1.1yrs

Average Tenure

56yo

Average Age

Experienced Management: CSBT.F's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Christopher Fair
CEO & Directorless than a yearCHF 1.34m0.35%
$ 3.5m
Joost de Bruijn
President of Innovation and Strategy & Executive Director6.4yrsCHF 873.70kno data
Clemens van Blitterswijk
Chairman7.4yrsCHF 92.60k1.94%
$ 19.1m
Oliver Walker
Independent Non-Executive Director6.4yrsCHF 73.80kno data
Cato Laurentin
Member of Advisory Boardno datano datano data
Ralph Müller
Member of Advisory Boardno datano datano data
Norbert Boos
Member of Advisory Boardno datano datano data
Thomas Steffen
Member of Advisory Boardno datano datano data
Andrew Sama
Member of Strategic Advisory Board6.2yrsno datano data
Richard Allen
Member of Strategic Advisory Board6.2yrsno datano data
Alpesh Patel
Member of Strategic Advisory Board6.2yrsno datano data
Kornelis Poelstra
Member of Strategic Advisory Board6.2yrsno datano data

6.2yrs

Average Tenure

56.5yo

Average Age

Experienced Board: CSBT.F's board of directors are considered experienced (6.2 years average tenure).